PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05721222 |
|
Recruitment Status :
Recruiting
First Posted : February 9, 2023
Last Update Posted : March 4, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1160 in participants with solid tumors.
Participants will have solid tumor or liquid cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
This Phase 1/2 study will have two parts. Part A of the study will find out how much and how frequently PRO1160 should be given to participants. Part B will use the dose and schedule found in Part A to find out how safe PRO1160 is and if it works to treat the diseases under study. The diseases under study will be Renal Cell Carcinoma (RCC),Nasopharyngeal Carcinoma (NPC) and Non-Hodgkin Lymphoma (NHL).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Renal Cell Carcinoma Nasopharyngeal Carcinoma Non Hodgkin Lymphoma | Drug: PRO1160 | Phase 1 Phase 2 |
This is a Phase 1/2 study of PRO1160, a CD70 targeted antibody-drug conjugate, to evaluate the safety, tolerability, PK, and antitumor activity of PRO1160 in patients with selected locally advanced /or metastatic solid and liquid tumors, including renal cell carcinoma, nasopharyngeal carcinoma and non-hodgkin lymphoma. This study consists of 2 parts, Part A: Dose Escalation and Part B: Dose Expansion.
Part A may evaluate up to 7 dose levels of PRO1160 on Day 1 of a 21 day cycle by IV infusion.
Part B will be initiated at a dose level based on a comprehensive analysis of safety, tolerability, clinical PK, PD and activity data from Part A in up to 4 different cohorts of up to 20 patients per cohort.
Patients will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 134 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase 1/2 Study of PRO1160 in Patients With Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC), or Non-Hodgkin Lymphoma (NHL) |
| Actual Study Start Date : | March 15, 2023 |
| Estimated Primary Completion Date : | April 30, 2024 |
| Estimated Study Completion Date : | April 30, 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: PRO1160
PRO1160 monotherapy in escalating doses in Part A and at the recommended phase 2 dose in Part B
|
Drug: PRO1160
Intravenous infusion of PRO1160 |
- Incidence of Treatment-Emergent Adverse Events [ Time Frame: Through end of treatment, up to approximately 1 year ]Type, incidence, severity, and seriousness of adverse events
- Dose limiting toxicity [ Time Frame: Through end of treatment, up to approximately 1 year ]The proportion of patients experiencing dose limiting toxicities
- Objective Response Rate [ Time Frame: Through end of treatment, up to approximately 1 year ]Patients who achieve partial or complete response per RECIST v1.1 criteria (RCC and NPC) and Lugano Classification 2014 (NHL)
- Disease Control Rate [ Time Frame: Through end of treatment, up to approximately 1 year ]Patients who achieve stable disease, partial or complete response per RECIST v1.1 criteria (RCC and NPC) and Lugano Classification 2014 (NHL)
- Progression-free survival [ Time Frame: Up to approximately 18 months ]Time from start of treatment to first documented disease progression or death
- Duration of objective response [ Time Frame: From date of enrollment until the date of first documented disease progression or date of study withdrawal, whichever came first, assessed up to 12 months ]Time from the first documentation of an objective tumor response (CR or PR) to the first documented tumor progression or death
- Peak Plasma Concentration (Cmax) for PRO1160 [ Time Frame: Through end of treatment, up to approximately 1 year ]Measurement of maximum plasma concentration after the administration of PRO1160
- Immunogenic potential of PRO1160 [ Time Frame: Through end of treatment, up to approximately 1 year ]Assessment of anti-drug antibodies
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pathologically confirmed metastatic or unresectable solid malignancy including Renal Cell carcinoma, Nasopharyngeal carcinoma or Stage III or IV Non Hodgkin Lymphoma
- Relapsed or refractory disease following prior systemic therapies known to confer medical benefit
- Willing to provide a tumor sample (archive tissue or fresh biopsy)
- ECOG performance status 0 or 1
- Measurable disease per RECIST v1.1 for RCC and NPC and per Lugano for NHL
Exclusion Criteria:
- Prior treatment with anti-CD70 directed therapy
- Other malignancy within 3 years
- Active CNS metastases (treated, stable CNS metastases are allowed)
- Uncontrolled Grade 3 or greater infection within 2 weeks
- Positive for HBV, HCV or HIV
- Use of a strong P450 CYP3A inhibitor within 14 days (dose escalation only)
- Additional protocol defined inclusion/exclusion criteria may apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05721222
| Contact: ProfoundBio Trial Support | 1-844-774-4232 | clinicaltrialinfo@profoundbio.com |
Show 17 study locations
| Responsible Party: | ProfoundBio US Co. |
| ClinicalTrials.gov Identifier: | NCT05721222 |
| Other Study ID Numbers: |
PRO1160-001 |
| First Posted: | February 9, 2023 Key Record Dates |
| Last Update Posted: | March 4, 2024 |
| Last Verified: | February 2024 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Lymphoma Carcinoma Lymphoma, Non-Hodgkin Carcinoma, Renal Cell Nasopharyngeal Carcinoma Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Neoplasms, Glandular and Epithelial Adenocarcinoma Kidney Neoplasms Urologic Neoplasms |
Urogenital Neoplasms Neoplasms by Site Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Kidney Diseases Urologic Diseases Male Urogenital Diseases Nasopharyngeal Neoplasms Pharyngeal Neoplasms Otorhinolaryngologic Neoplasms Head and Neck Neoplasms Nasopharyngeal Diseases Pharyngeal Diseases Stomatognathic Diseases |